Image of two soldiers looking at a drone
Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Artificial intelligence-based defense technology designer Droneshield Ltd (ASX:DRO) has seen its share price spike up more than 4% on news of a $13.5 million contract from a US government customer for its dismounted Counter-UxS (or C-UxS) systems.

The contract was for a repeat order of the C-UxS systems – which target multi-domain aerial, ground and maritime surface drones – with the product delivery and cash receipt both factored into for completion by the end of 2024.

Droneshield director of Business Development Tom Branstetter said the contract was evidence of client confidence in the company’s suite of drone defense products.

“DroneShield’s ability to rapidly deliver high-performance, lifesaving technology at this scale sets us apart in the counter-UAS industry, empowering our clients with cutting-edge solutions precisely when they need it,” he said.

At 10:49 AEDT, shares in Droneshield were trading at $1.40 – a rise of 4.89% since the market opened.

Join the discussion: See what HotCopper users are saying about Droneshield and be part of the conversations that move the markets.

DRO by the numbers
More From The Market Online
A yurt located on some Mongolian plane

TMK Energy kicks off drilling for new pilot wells in Mongolia’s vastly underexplored Gobi

TMK Energy (ASX:TMK) has kicked off a fresh round of drilling at its mammoth Gurvantes XXXV…
The Market Online Video

ASX Market Close: Iron Ore falls after China stimulus disappoints investors | October 8, 2024

The ASX200 closed down 0.35% at 8,176 points. Iron ore prices fell from US$114/tn to US$108/tn…
The Market Online Video

ASX Market Update: Rinehart down sizes Mulga Downs iron ore mine | October 8, 2024

The ASX200 has been down 0.11% at 8,205 points in early afternoon trade. Investors’ bullish expectations…
Burn wound care

Orthocell wins first international approval for nerve repair product

West Australia-based regenerative medicine play Orthocell (ASX: OCC) has received regulatory approval from the Health Sciences…